PAPP-A2 may induce augmented IGF signaling in tumor cells, and further studies to test this hypothesis could lead to the establishment of PAPP-A2 as a prognostic marker or a biomarker for IGF-I targeted therapy. The gene discussed is PAPPA2; the disease is neoplasm.